BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 16630140)

  • 41. Induction of adipophilin-specific cytotoxic T lymphocytes using a novel HLA-A2-binding peptide that mediates tumor cell lysis.
    Schmidt SM; Schag K; Müller MR; Weinschenk T; Appel S; Schoor O; Weck MM; Grünebach F; Kanz L; Stevanovic S; Rammensee HG; Brossart P
    Cancer Res; 2004 Feb; 64(3):1164-70. PubMed ID: 14871853
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Immunization of patients with the hTERT:540-548 peptide induces peptide-reactive T lymphocytes that do not recognize tumors endogenously expressing telomerase.
    Parkhurst MR; Riley JP; Igarashi T; Li Y; Robbins PF; Rosenberg SA
    Clin Cancer Res; 2004 Jul; 10(14):4688-98. PubMed ID: 15269141
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Screening of HLA-A24-restricted epitope peptides from prostate-specific membrane antigen that induce specific antitumor cytotoxic T lymphocytes.
    Horiguchi Y; Nukaya I; Okazawa K; Kawashima I; Fikes J; Sette A; Tachibana M; Takesako K; Murai M
    Clin Cancer Res; 2002 Dec; 8(12):3885-92. PubMed ID: 12473604
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Identification of a novel HLA-A2-restricted cytotoxic T lymphocyte epitope from cancer-testis antigen PLAC1 in breast cancer.
    Liu W; Zhai M; Wu Z; Qi Y; Wu Y; Dai C; Sun M; Li L; Gao Y
    Amino Acids; 2012 Jun; 42(6):2257-65. PubMed ID: 21710262
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Identification of an HLA-A2-restricted epitope peptide derived from hypoxia-inducible protein 2 (HIG2).
    Yoshimura S; Tsunoda T; Osawa R; Harada M; Watanabe T; Hikichi T; Katsuda M; Miyazawa M; Tani M; Iwahashi M; Takeda K; Katagiri T; Nakamura Y; Yamaue H
    PLoS One; 2014; 9(1):e85267. PubMed ID: 24416375
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Identification of a novel HLA-A 02:01-restricted cytotoxic T lymphocyte epitope derived from the EML4-ALK fusion gene.
    Yoshimura M; Tada Y; Ofuzi K; Yamamoto M; Nakatsura T
    Oncol Rep; 2014 Jul; 32(1):33-9. PubMed ID: 24842630
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Identification of a new HLA-A*0201-restricted cryptic epitope from CYP1B1.
    Maecker B; von Bergwelt-Baildon MS; Sherr DH; Nadler LM; Schultze JL
    Int J Cancer; 2005 Jun; 115(2):333-6. PubMed ID: 15688394
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Identification and modification of an HLA-A*0201-restricted cytotoxic T lymphocyte epitope from Ran antigen.
    Li F; Yang D; Wang Y; Liu B; Deng Y; Wang L; Shang X; Tong W; Ni B; Wu Y
    Cancer Immunol Immunother; 2009 Dec; 58(12):2039-49. PubMed ID: 19430788
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Identification of peptide vaccine candidates sharing among HLA-A3+, -A11+, -A31+, and -A33+ cancer patients.
    Takedatsu H; Shichijo S; Katagiri K; Sawamizu H; Sata M; Itoh K
    Clin Cancer Res; 2004 Feb; 10(3):1112-20. PubMed ID: 14871991
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The forkhead box M1 transcription factor as a candidate of target for anti-cancer immunotherapy.
    Yokomine K; Senju S; Nakatsura T; Irie A; Hayashida Y; Ikuta Y; Harao M; Imai K; Baba H; Iwase H; Nomori H; Takahashi K; Daigo Y; Tsunoda T; Nakamura Y; Sasaki Y; Nishimura Y
    Int J Cancer; 2010 May; 126(9):2153-63. PubMed ID: 19688828
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Proliferation potential-related protein, an ideal esophageal cancer antigen for immunotherapy, identified using complementary DNA microarray analysis.
    Yoshitake Y; Nakatsura T; Monji M; Senju S; Matsuyoshi H; Tsukamoto H; Hosaka S; Komori H; Fukuma D; Ikuta Y; Katagiri T; Furukawa Y; Ito H; Shinohara M; Nakamura Y; Nishimura Y
    Clin Cancer Res; 2004 Oct; 10(19):6437-48. PubMed ID: 15475430
    [TBL] [Abstract][Full Text] [Related]  

  • 52. An HLA-A24-restricted cytotoxic T lymphocyte epitope of a tumor-associated protein, survivin.
    Hirohashi Y; Torigoe T; Maeda A; Nabeta Y; Kamiguchi K; Sato T; Yoda J; Ikeda H; Hirata K; Yamanaka N; Sato N
    Clin Cancer Res; 2002 Jun; 8(6):1731-9. PubMed ID: 12060610
    [TBL] [Abstract][Full Text] [Related]  

  • 53. HLA-A2-restricted cytotoxic T lymphocyte epitopes from human heparanase as novel targets for broad-spectrum tumor immunotherapy.
    Chen T; Tang XD; Wan Y; Chen L; Yu ST; Xiong Z; Fang DC; Liang GP; Yang SM
    Neoplasia; 2008 Sep; 10(9):977-86. PubMed ID: 18714399
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A novel DNA methyltransferase I-derived peptide eluted from soluble HLA-A*0201 induces peptide-specific, tumor-directed cytotoxic T cells.
    Berg M; Barnea E; Admon A; Zavazava N
    Int J Cancer; 2004 Nov; 112(3):426-32. PubMed ID: 15382068
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Rationale for antiangiogenic cancer therapy with vaccination using epitope peptides derived from human vascular endothelial growth factor receptor 2.
    Wada S; Tsunoda T; Baba T; Primus FJ; Kuwano H; Shibuya M; Tahara H
    Cancer Res; 2005 Jun; 65(11):4939-46. PubMed ID: 15930316
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Determination of cellularly processed HLA-A2402-restricted novel CTL epitopes derived from two cancer germ line genes, MAGE-A4 and SAGE.
    Miyahara Y; Naota H; Wang L; Hiasa A; Goto M; Watanabe M; Kitano S; Okumura S; Takemitsu T; Yuta A; Majima Y; Lemonnier FA; Boon T; Shiku H
    Clin Cancer Res; 2005 Aug; 11(15):5581-9. PubMed ID: 16061876
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Functional detection of epithelial cell adhesion molecule specific cytotoxic T lymphocytes in patients with lung cancer, colorectal cancer and in healthy donors.
    Trojan A; Tun-Kyi A; Odermatt B; Nestle FO; Stahel RA
    Lung Cancer; 2002 May; 36(2):151-8. PubMed ID: 11955649
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A HER2/NEU-derived peptide, a K(d)-restricted murine tumor rejection antigen, induces HER2-specific HLA-A2402-restricted CD8(+) cytotoxic T lymphocytes.
    Ikuta Y; Okugawa T; Furugen R; Nagata Y; Takahashi Y; Wang L; Ikeda H; Watanabe M; Imai S; Shiku H
    Int J Cancer; 2000 Aug; 87(4):553-8. PubMed ID: 10918197
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Peptide FLNPDVLDI of heparanase is a novel HLA-A2-restricted CTL epitope and elicits potent immunological antitumor effects in vitro with an 8-branched design.
    Zhang J; Yang J; Fan D; Tao H; Wang H; Yu T
    Oncol Rep; 2013 May; 29(5):1955-61. PubMed ID: 23503586
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prediction and identification of HLA-A*0201-restricted epitopes from cancer testis antigen CT23.
    Zeng X; Nong WX; Zou XQ; Li F; Ge YY; Zhang QM; Luo B; Huang W; Zou JX; Fan R; Xie XX
    Hum Vaccin Immunother; 2023 Dec; 19(3):2293299. PubMed ID: 38100550
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.